MRT bei neurodegenerativen Erkrankungen

Neurodegenerative Erkrankungen nehmen in einer älter werdenden Gesellschaft stark zu. Bei klinischem Verdacht lassen sich diese Erkrankungen häufig anhand krankheitsspezifischer Atrophiemuster diagnostizieren. Die Erkennung wird erleichtert, wenn der Datensatz des Patienten mit einer Gruppe „alters- und geschlechtsgematchter“ Kontrollen verglichen und Voxel bzw. Regionen, die sich unterscheiden, hervorgehoben werden.

According to the German S3 guideline dementia every patient with a dementia disorder should have a MRI. The goal is not only to uncover treatable conditions but also to detect region-specific atrophy pattern which are characteristic of primary dementia disorders such as Alzheimer’s disease, fronto-temporal lobar degeneration and others. Diagnostic accuracy can be improved by Voxel- and Region-based volumetric analysis of the individual brain compared to age-matched controls.

Schlüsselwörter

Magnetresonanztomografie - neurodegenerative - Erkrankungen - Morbus Alzheimer

Keywords

MRI - neurodegenerative diseases - Alzheimerʼs disease

Publikationsverlauf

Artikel online veröffentlicht:
23. April 2020

• Literatur

• 1 Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie. S3-Leitlinie „Demenzen“. Im Internet:. https://www.awmf.org/uploads/tx_szleitlinien/038-013l_S3-Demenzen-2016-07.pdf; Stand: 30.04.2019
• 2 Ziegler U, Doblhammer G. Prevalence and incidence of dementia in Germany – a study based on data from the public sick funds in 2002. Gesundheitswesen 2009; 71: 281-290
• 3 Mackenzie IR, Rademakers R, Neumann M. TDP‑43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol 2010; 9: 995-1007 . doi:10.1016/S1474-4422 (10)70195-2
• 4 Jack CR jr, Knopman DS, Jagust WJ. et al. Hypothetical model of dynamic biomarkers of the Alzheimerʼs pathological cascade. Lancet Neurol 2010; 9: 119-128. doi:10.1016/S1474-4422(09)70299-6
• 5 Qiu C, De Ronchi D, Fratiglioni L. The epidemiology of the dementias: an update. Curr Opin Psychiatry 2007; 20: 380-385
• 6 Klöppel S, Peter J, Ludl A. et al. Applying Automated MR-Based Diagnostic Methods to the Memory Clinic: A Prospective Study. J Alzheimers Dis 2015; 47: 939-954. doi:10.3233/JAD-150334
• 7 Weder ND, Aziz R, Wilkins K, Tampi RR. Frontotemporal dementias: a review. Ann Gen Psychiatry 2007; 6: 15
• 8 Buter TC, van den Hout A, Matthews FE. et al. Dementia and survival in Parkinson disease: a 12-year population study. Neurology 2008; 70: 1017-1022
• 9 Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 2005; 34: 561-566
• 10 Gifford DR, Hollaway RG, Vickrey BG. Systematic review of clinical prediction rules for neuroimaging in the evaluation of dementia. Arch Intern Med 2000; 160: 2855-2862
• 11 Hejl A, Høgh P, Waldemar G. Potentially reversible conditions in 1000 consecutive memory clinic patients. J Neurol Neurosurg Psychiatry 2002; 73: 390-394
• 12 Engel DC, Adib SD, Schuhmann MU. et al. Paradigm-shift: radiological changes in the asymptomatic iNPH-patient to be: an observational study. Fluids Barriers CNS 2018 15: 5.
• 13 Ishii K, Kanda T, Harada A. et al. Clinical impact of the callosal angle in the diagnosis of idiopathic normal pressure hydrocephalus. Eur Radiol 2008; 18: 2678-2683 . doi:10.1007/s00330-008-1044-4
• 14 Scheltens P, Leys D, Barkhof F. et al. Atrophy of medial temporal lobe on MRI in “probable” Alzheimerʼs disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992; 55: 967-972
• 15 Koedam EG, Lehmann M, van der Flier WM. et al. Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol 2011; 21: 2618-2625
• 16 Westman E, Cavalin L, Muehlboeck JS. et al. Sensitivity and Specificity of Medial Temporal Lobe Visual Ratings and Multivariate Regional MRI Classification in Alzheimerʼs Disease. PLoS One. 2011 6. e22506 . doi:10.1371/journal. pone.0022506
• 17 Braak H, Braak E. Neuropathological stageing of Alzheimer-related change. Acta Neuropathol 1991; 82: 239
• 18 Enkirch SJ, Traschütz A, Müller A. et al. The ERICA Score: An MR Imaging-based Visual Scoring System for the Assessment of Entorhinal Cortex Atrophy in Alzheimer Disease. Radiology 2018; 288: 226-333
• 19 Massey LA, Jäger HR, Paviour DC. et al. The midbrain to pons ratio: A simple and specific MRI sign of progressive supranuclear palsy. Neurology 2013; 80: 1856-1861
• 20 Morelli M, Arabia G, Salsone M. Accuracy of magnetic resonance parkinsonism index for differentiation of progressive supranuclear palsy from probable or possible Parkinson disease. Mov Disord 2011; 26: 527-533 . doi:10.1002/mds.23529
• 21 Shattuck DW, Mirza M, Adisetiyo V. et al. Construction of a 3 D probabilistic atlas of human cortical structures. Neuro-Image 2008; 39: 1064-1080 . doi:10.1016/j.neuroimage. 2007.09.031
• 22 Klöppel S, Yang S, Kellner E. et al. Voxel-wise deviations from healthy aging for the detection of region-specific atrophy. Neuroimage Clin. 2018 20. 851-860 . doi:10.1016/j. nicl.2018.09.013
• 23 Faellmar D, Haller S, Lilja JM. et al. Arterial spin labeling-based Z-maps have high specificity and positive predictive value for neurodegenerative dementia compared to FDG‑PET. Eur Radiol 2017; 27: 4237-4246
• 24 Dubois B, Feldman HH, Jacova C. et al. Advancing research diagnostic criteria for Alzheimerʼs disease: the IWG‑2 criteria. Lancet Neurol 2014; 13: 614-629 . doi:10.1016/S1474-4422 (14)70090-0
• 25 Hachinski VC, Iliff LD, Zilhka E. et al. Cerebral blood flow in dementia. Arch Neurol 1975; 32: 632-637
• 26 Roman GC, Tatemichi TK, Erkinjuntti T. et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993 43. 250-260
• 27 Rascovsky K, Hodges JR, Knopman D. et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011; 134: 2456-2477
• 28 Gorno-Tempini ML, Hillis AE, Weintraub S. et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76: 1006-1014
• 29 Rohrer J, Warren JD. Phenotypic signatures of genetic frontotemporal dementia. Curr Opin Neurol 2011; 24: 542-549
• 30 Schwarz ST, Afzal M, Morgan PS. et al. The ‘Swallow Tail’ Appearance of the Healthy Nigrosome – A New Accurate Test of Parkinsonʼs Disease: A Case-Control and Retrospective Cross-Sectional MRI Study at 3 T. PLoS One 2014; 9: e93814. doi:10.1371/journal.pone.0093814
• 31 Höglinger GU, Respondek G, Stamelou M. et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord 2017; 32: 853-864. doi:10.1002/mds.26987
• 32 Sakurai K, Tokumaru AM, Shimoji K. et al. Beyond the midbrain atrophy: wide spectrum of structural MRI finding in cases of pathologically proven progressive supranuclear palsy. Neuroradiology 2017; 59: 431-443
• 33 McKeith IG, Boeve BF, Dickson DW. et al. Diagnosis and management of dementia with Lewy bodies. Neurology 2017; 89: 88-100 doi:10.1212/WNL.0000000000004058